The cell-cycle G2/M phase gene UBE2C is overexpressed in various solid tumors including castration-resistant prostate cancer (CRPC). Our recent studies found UBE2C to be a CRPC-specific androgen receptor (AR) target gene that is necessary for CRPC growth, providing a potential novel target for therapeutic intervention. Here we demonstrate that the G1/S cell-cycle inhibitor-779 (CCI-779), an mTOR inhibitor, inhibited UBE2C mRNA and protein expression in AR-positive CRPC cell models abl and C4-2B. Treatment with CCI-779 significantly decreased abl cell proliferation in vitro and in vivo through inhibition of cell-cycle progression of both G2/M and G1/S phases.
Introduction
The androgen receptor (AR), a ligand-dependent transcription factor, is expressed in both androgen-dependent prostate cancer (ADPC) and castration-resistant prostate cancer (CRPC) (1, 2) . One important function of AR in prostate cancer is to drive cellcycle progression (3) . While it is well known that AR mainly regulates cell-cycle G1/S transition in ADPC through AR-dependent regulation of CCND1, p21 and p27 (3) , recent integrated analysis of AR cistrome and gene expression data in prostate cancer found that AR selectively binds to the enhancers of G2/M phase genes in CRPC but not in ADPC, leading to higher G2/M phase gene expression and accelerated cell-cycle G2/M progression in CRPC versus ADPC (4, 5) .
One of such AR-regulated G2/M phase genes in CRPC is UBE2C, a gene whose translation product is an anaphase promoting complex/cyclosome (APC/C)-specific E2 ubiquitin-conjugating enzyme (6) . Significantly, UBE2C mRNA and protein expression levels are overexpressed in CRPC cases (4, 7, 8) . Consistent with the essential role of UBE2C in driving M-phase cell cycle progression by inactivating the M-phase check point (9) or increasing the pool of active APC/C (10), silencing of UBE2C in CRPC cells arrests cell-cycle in G2/M phase and decreases CRPC cell proliferation, suggesting that screening to have significant efficacy and potency in inhibition of UBE2C protein and mRNA expression in AR-positive CRPC cell lines abl and C4-2B. Although previous studies found that mTOR inhibitors including CCI-779 decreases the growth of cancer cell lines (e.g. AR-negative CRPC cell lines PC-3 and DU-145) via G1/S inhibition (12, 13) , we show that CCI-779 inhibits the abl in vitro and in vivo growth by blocking both cell-cycle G2/M and G1/S transitions. Consistent with the newly identified role of UBE2C in promoting tumor invasion and metastasis (14) (15) (16) , we find that CCI-779 treatment decreases UBE2C-dependent cell invasion of abl and C4-2B cells. Finally, we find that the combined effects on attenuating UBE2C transcription and mRNA stability of CCI-779 lead to decreased mRNA levels of UBE2C. Collectively, this study identifies CCI-779 as a UBE2C inhibitor in CRPC.
Materials and Methods

Reagents and cell culture
CCI-779 (temsirolimus) was purchased from LC Laboratories (Woburn, MA).
LNCaP cells were obtained from American Type Culture Collection (ATCC) and C4-2B cells were purchased from ViroMed Laboratories (Minneapolis, MN). LNCaP and C4-2B cells were cultured in RPMI1640 media (Invitrogen, Carlsbad, CA) supplemented with containing 10% charcoal-stripped FBS. All three cell lines were passaged in our laboratory for less than 6 months after resuscitation.
Western blot
Cells or tumor tissues were collected and lysed as previously described (18) . The total lysate sample (50 µg per lane) was resolved by SDS-PAGE and immunoblotted with primary antibodies. Antibodies against various proteins were purchased from the following sources: anti-UBE2C (A650) from Boston Biochem (Cambridge, MA); anti-AR (441), anti-GATA2 (H116), anti-SRC1 (M341), anti-p300 (C20), anti-MED1 (M255) from Santa Cruz Biotechnology (Santa Cruz, CA); anti-CCND1 (ab24249) and antiFoxA1 (ab23738) from Abcam (Cambridge, MA); anti-calnexin from Stressgen (Victoria BC, Canada), and anti-β-actin from Sigma-Aldrich (St. Louis, MO). An anti-SRC3 antibody has been described previously (19) .
Real-time RT-PCR
Total RNA was isolated from cells using Trizol reagent (Invitrogen). Real time RT-PCR was performed on 100 ng of RNA by using MultiScribe reverse transcriptase and SYBR Green PCR kit (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. The following primers were used: UBE2C (5'-and 5'-TCGCCCCACTTGATTTTGG -3') (19) , and actin (5'-AGGCACCAGGGCGTGAT-3' and 5'-GCCCACATAGGAATCCTTCTGAC-3') (21) . TM   siRNAs targeting CCND1 and UBE2C (siCCND1 and siUBE2C) and ON-TARGET plus TM control siRNA (siControl) were purchased from Dharmacon (Lafayette, CO). siRNAs were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
RNA interference
ON-TARGET plus
Synchronization and fluorescence-activated cell sorting (FACS) analysis
Cells were arrested in G2/M phase by using a thymidine-nocodazole block as previously described (22). Briefly, cells were first synchronized by arresting them at the G1/S border with 2 mM thymidine for 24 hours, followed by a 4-hour release, and then arrested at M phase with 100 ng/ml nocodazole for 12 hours. CCI-779 (50 nM) or vehicle control was added at the same time as nocodazole. The cells were released from the nocodazole block with two washes of fresh medium and allowed to progress to G1/S phase. Cells were collected after the release (2 hours for abl cells, 1 hour for C4-2B cells and Body weight was also monitored bi-weekly. After 4 weeks, mice were euthanized and tumor tissues were weighed and subjected for western blot analysis.
Research. FBS. Both chambers were treated with 50 nM CCI-779 or vehicle. The cells were allowed to invade for 48 hours. The cells on the underside of the filter were then fixed with 80% methanol, stained by 0.3% crystal violet and counted using light microscopy.
The invasion results were normalized by cell proliferation under the same treatment conditions.
Chromatin immunoprecipitation (ChIP) and ReChIP
ChIP was performed as previously described (19) . The antibodies used were anti-AR (N20), anti-GATA2 (H116), anti-SRC1 (M341), anti-SRC3, anti-p300 (C20), anti-MED1 (M255) from Santa Cruz Biotechnology (Santa Cruz, CA); anti-FoxA1 (ab23738) from Abcam (Cambridge, MA); and anti-RNA pol II (8WG16) from Covance (Berkeley, CA). SRC3 ChIP was performed with SRC3 antibodies as previously described (19) . The ChIP-enriched DNA was then quantified by qPCR using specific primers for the UBE2C enhancers 1 and 2 (4), and the UBE2C promoter, respectively. Negative controls used were sequences containing androgen responsive elements (AREs) that do not have actual ReChIP assays were performed as previously described (25).
mRNA stability assay abl cells were treated with 50 nM CCI-779 or vehicle. At the same time, 5 µg/ml actinomycin D (Sigma) was used to block mRNA synthesis. Cells were collected at various time points (0, 6, 9, 12, 18 and 24 hours) after treatment and UBE2C mRNA level was quantified by qRT-PCR. The t 1/2 was calculated using the iterative curve fitting software SigmaPlot (SPSS), by fitting four-parameter exponential decay curves described by formula y=a*exp (b/(c*x+d)). Estimations of c, designated as C, and corresponding standard errors, designated as SE(C), were used to calculate standard error (t 1/2 = log (2)/C). t 1/2 ± SE(t 1/2 ) was calculated as [log(2)/(C + SE(C)), log(2)/(C -SE(C))].
Results
CCI-779 down-regulates UBE2C protein and mRNA expression levels in CRPC and
ADPC cells
Research. (4, 7, 8) .
CCI-779 emerged from screening as it potently decreased both protein and mRNA levels of UBE2C in abl cells (Figs. 1A and 1B) . We further extended our study to another CRPC cell model C4-2B that overexpresses the AR (26). We confirmed that UBE2C protein and mRNA levels were significantly decreased in CCI-779 treated C4-2B cells (Fig. 1D ). These results indicate that CCI-779 can directly decrease UBE2C mRNA expression in a CCND1 expression-and G1 arrest-independent manner.
We obtained essentially similar results in C4-2B cells ( Supplementary Fig. S1 ).
CCI-779 blocks both G2/M and G1/S cell-cycle progression and decreases cell proliferation in CRPC and ADPC cells
As UBE2C plays an essential role in promoting G2/M phase cell-cycle progression in prostate cancer cells (4) and CCI-779 inhibited UBE2C expression ( To further delineate the role of UBE2C in CCI-779-mediated CRPC cell proliferation inhibition, the effects of CCI-779 on cell proliferation of UBE2C silenced or control silenced abl and C4-2B cells were examined. The inhibitory effect of CCI-779 on abl cell proliferation was markedly decreased in UBE2C silenced (28%) versus control silenced (45%) abl cells (Fig. 2D) , suggesting that UBE2C silencing-mediated abl cell growth inhibition (Fig. 2D ) significantly contributes to growth inhibitory effect of CCI-779 on abl (Fig. 2C ). By contrast, as UBE2C silencing only slightly decreased C4-2B cell proliferation ( Fig. 2D ), CCI-779-mediated inhibition of C4-2B cell proliferation ( Fig. 2C) was presumably mostly due to CCI-779-induced decreased expression of CCND1 rather than UBE2C in C4-2B cells (Figs. 1A and 2D).
CCI-779 inhibits in vivo growth of abl xenograft through downregulation of UBE2C and CCND1
We further extended our studies to an in vivo xenograft model to validate the further supported our findings, as the average value was 78.6 ± 15.5 mg for control group as compared with 13.5 ± 2.5 mg for CCI-779 group (Fig. 3C ). More importantly, western blot analysis confirmed that both UBE2C and CCND1 protein levels were significantly decreased in tumor tissues following treatment with CCI-779 (Fig. 3D) . These data suggest that CCI-779 significantly decreases CRPC cell in vivo growth through inhibition of UBE2C and CCND1. Similar effect of CCI-779 on CRPC cell growth and protein expression of CCND1 and UBE2C was observed in castrated mice (Supplementary Fig.   S2 ).
CCI-779 inhibits UBE2C-dependent CRPC cell invasion in vitro
The role of UBE2C is not limited to promoting cell growth. Recent studies have found that UBE2C expression is positively correlated with metastasis in patients with various cancer types, including colorectal cancer (14) , breast cancer (15) and soft tissue tumors (16) . Consistent with these clinical observations, an in vitro study has demonstrated that UBE2C downregulation and overexpression decreases and increases invasiveness of a human colon cancer cell line HT-29, respectively (14) . To investigate whether UBE2C expression affects abl, C4-2B and LNCaP cell invasion, we transfected a siRNA targeting UBE2C (siUBE2C) or a control siRNA (siControl), or UBE2C vector or a control vector in all three cell lines ( (Fig. 4C, and Supplementary Fig. S3 ).
Importantly, UBE2C overexpression reversed most of this CCI-779-induced invasion inhibitory effect ( Fig. 4C and Supplementary Fig. S3 ). These results suggest that CCI-779-induced prevention of CRPC cell invasion is mediated mostly by UBE2C.
Mechanisms for CCI-779 inhibition on UBE2C mRNA expression in CRPC cells
To investigate the underlying mechanisms for UBE2C mRNA inhibition by CCI-779 in CRPC cells, we first examined the effect of CCI-779 on recruitment of AR, its collaborating transcription factors FoxA1 and GATA2 (25), and its coactivators histone acetyltransferases (HAT) (SRC1, SRC3, p300), and Mediator subunit (MED1) (19) to the two UBE2C enhancers located -32.8 kb and +41.6 kb away from the transcription start site (TSS) of UBE2C gene in abl cells (4) . abl cells were treated with CCI-779, and ChIP assays were performed using antibodies against AR, FoxA1, GATA2, SRC1, SRC3, p300, MED1 and RNA polymerase II (pol II). While exposure to CCI-779 did not affect AR binding at the two UBE2C enhancers, CCI-779 treatment decreased and increased FoxA1/GATA2 recruitment to the UBE2C enhancers 1 and 2, respectively (Figs. 5A-5C ).
Significantly, CCI-779 treatment attenuated the recruitment of AR coactivators SRC1, SRC3, p300 and MED1 to both UBE2C enhancers but not the two negative control (Figs. 5D-5G) . Consistent with the notion that HAT modifies chromatin structure to allow Mediator facilitating pol II recruitment to target gene promoters (27-29), exposure to CCI-779 significantly reduced the pol II level at the UBE2C promoter (Fig.   5H ).
Since exposure to CCI-779 had no effect on protein expression levels of these coactivators (Fig. 5I) 
Discussion
The AR is often expressed and functional in most CRPC patients and current clinical studies on CRPC focus on targeting AR itself using AR antagonists [e.g. MDV-3100 (30)] or inhibitors of androgen synthesis [e.g. abiraterone acetate (31) ]. Although these agents decrease CRPC growth in some patients, elimination of all AR activity blocks some beneficial actions of AR (e.g. inhibition of some oncogenes like PCDH11 (32) ) and contributes to undesirable effects such as bone loss (33) In this study, we identified the mTOR inhibitor CCI-779 as an inhibitor for UBE2C in CRPC cells. We showed that CCI-779 treatment significantly decreases UBE2C mRNA and protein expression in CRPC cells at its pharmacologically attainable concentrations in clinical trials (35, 36) (Fig.1) . Although it is well known that inhibition of mTOR decreases protein expression levels of some genes by dephosphorylation of p70 ribosomal S6 kinase (S6K1) and the eukaryotic initiation factor 4E binding protein 1 (4E-BP1) (12, 37) , recent studies have found that mTOR inhibitors also decreases RNA levels of some genes (37, 38) (Fig.5) . Interestingly, we also found that CCI-779 attenuates UBE2C mRNA stability (Fig.6) , suggesting that CCI-779-induced direct downregulation of UBE2C mRNA levels is caused by decreased UBE2C mRNA transcription and stability. decreased effect of mTOR inhibitors on inhibition of cell proliferation (42, 44). However, as the AR target genes examined in these studies (42, 44) are not directly relevant to cell growth and invasion, it is not very clear that the failure of mTOR inhibitors as monotherapy is caused by mTOR inhibitor-activated AR signaling. Interestingly, our studies found that CCI-779 significantly decreases the expression of a CRPC-specific AR target gene UBE2C in CRPC cell models abl and C4-2B (Fig. 1) . The overexpressed UBE2C in abl and C4-2B cells compared to LNCaP cells (4) plays a critical role in cell proliferation and/or invasion (Figs. 2-4) (4). CCI-779, acting partially through a UBE2C-dependent mechanism, significantly decreases abl cell growth in vitro and in vivo (Figs. 2   and 3 ). Importantly, we also found that CCI-779-induced inhibition of abl and C4-2B cell invasion is mediated mostly by UBE2C (Fig.4) . Although the average level of UBE2C expression in CRPC patients is significantly higher than that in ADPC patients, UBE2C expression in CRPC cases is highly variable (4). Thus it is possible that those CRPC patients with high UBE2C expression will have better therapeutic response for CCI-779 than those with low UBE2C expression. Future studies will be needed to investigate whether UBE2C is able to serve as a biomarker for predicting CCI-779 therapy response in CRPC patients.
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